Candela curbs personnel
This article was originally published in The Gray Sheet
Executive Summary
Boston-based aesthetic laser developer will cut 15 positions and reduce the salaries of 50 additional employees in an attempt to add $2 mil. to its annual bottom line, the company announces during an April 30 earnings call. Sales for the first quarter of 2002 were down 14% over the same period in 2001, from $18.8 mil. to $16.1 mil., and the firm posted a loss of $291,000 ($0.03 per share) for the quarter, compared to a profit of $1.55 mil. ($0.14 per share) in the year-ago period. Growth is expected following 510(k) clearances for the Vbeam and Smoothbeam laser systems in March, and the Cbeam psoriasis and surgical scar treatment system in January...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.